Remifentanil Hydrochloride has 27 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 20 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Monoamine Oxidase Inhibitors (Maois), Alcohol, Anakinra. Patients taking Remifentanil Hydrochloride should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 27
- Contraindicated
- 1
- Major
- 20
- Moderate
- 6
Contraindicated (1)
- Remifentanil Hydrochloride + Monoamine Oxidase Inhibitors (Maois)— May manifest as serotonin syndrome or opioid toxicity. Not recommended for patients taking MAOIs or within 14 days of st…
Major (20)
- Remifentanil Hydrochloride + Alcohol— CNS depressant that increases risk of hypotension, respiratory depression, profound sedation, coma, and death when combi…
- Remifentanil Hydrochloride + Anakinra— Concomitant use may result in serotonin syndrome.
- Remifentanil Hydrochloride + Cyclobenzaprine— Concomitant use may result in serotonin syndrome.
- Remifentanil Hydrochloride + Gabapentin— Gabapentinoid CNS depressant increases risk of hypotension, respiratory depression, profound sedation, coma, and death.
- Remifentanil Hydrochloride + Linezolid— MAOI activity may result in serotonin syndrome or opioid toxicity.
- Remifentanil Hydrochloride + Metaxalone— Concomitant use may result in serotonin syndrome.
- Remifentanil Hydrochloride + Methylene Blue— MAOI activity may result in serotonin syndrome or opioid toxicity.
- Remifentanil Hydrochloride + Mirtazapine— Concomitant use may result in serotonin syndrome.
- Remifentanil Hydrochloride + Muscle Relaxants— CNS depressants increase risk of hypotension, respiratory depression, profound sedation, coma, and death.
- Remifentanil Hydrochloride + Nitrazepam— Additive CNS depression increases risk of hypotension, respiratory depression, profound sedation, coma, and death.
- Remifentanil Hydrochloride + Other Anticholinergic Agents— CNS depressants increase risk of hypotension, respiratory depression, profound sedation, coma, and death.
- Remifentanil Hydrochloride + Pregabalin— Gabapentinoid CNS depressant increases risk of hypotension, respiratory depression, profound sedation, coma, and death.
- Remifentanil Hydrochloride + Sedatives— CNS depressants increase risk of hypotension, respiratory depression, profound sedation, coma, and death.
- Remifentanil Hydrochloride + Selective Serotonin Reuptake Inhibitors (Ssri)— Concomitant use may result in serotonin syndrome.
- Remifentanil Hydrochloride + Tcas— Concomitant use may result in serotonin syndrome.
- Remifentanil Hydrochloride + Topical Local Anesthetics— CNS depressants increase risk of hypotension, respiratory depression, profound sedation, coma, and death.
- Remifentanil Hydrochloride + Tramadol— Concomitant use may result in serotonin syndrome.
- Remifentanil Hydrochloride + Tranquilizers— CNS depressants increase risk of hypotension, respiratory depression, profound sedation, coma, and death.
- Remifentanil Hydrochloride + Trazodone— Concomitant use may result in serotonin syndrome.
- Remifentanil Hydrochloride + Triptans— Concomitant use may result in serotonin syndrome.
Moderate (6)
- Remifentanil Hydrochloride + Buprenorphine— Partial agonist opioid may reduce analgesic effect of remifentanil and/or precipitate withdrawal symptoms.
- Remifentanil Hydrochloride + Butorpenol— Mixed agonist/antagonist may reduce analgesic effect of remifentanil and/or precipitate withdrawal symptoms.
- Remifentanil Hydrochloride + Mixed Agonist/Antagonist And Partial Agonist Opioid Analgesics— May reduce analgesic effect and/or precipitate withdrawal symptoms. Careful observation during treatment initiation and …
- Remifentanil Hydrochloride + Mixed Agonist/Antagonist Opioid Analgesics— May reduce analgesic effect and/or precipitate withdrawal symptoms. Careful observation during treatment initiation and …
- Remifentanil Hydrochloride + Nalbuphine— Mixed agonist/antagonist may reduce analgesic effect of remifentanil and/or precipitate withdrawal symptoms.
- Remifentanil Hydrochloride + Pentazocine— Mixed agonist/antagonist may reduce analgesic effect of remifentanil and/or precipitate withdrawal symptoms.